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1. Introduction 
One major limitation in the development of effective and targeted cancer therapies is the 
incomplete understanding of the molecular mechanisms driving malignant cell growth and 
the resistance of residual cancer stem cells to standard therapies, such as chemotherapy 
and radiation. Consequently, numerous attempts have been made to elucidate the molecular 
circuits initiating and perpetuating malignant cell transformation.  
Among the different cancer entities, leukemias harbor only a few mutations and therefore 
represent a good model system for the study of oncogenesis. The cloning and subsequent 
analysis of leukemia-associated gene products have strongly facilitated the understanding 
of their biological function and the development of appropriate model systems. In early 
experiments, leukemia-associated oncogenes were ectopically expressed in fibroblasts, a cell 
type which is not optimal for modeling leukemia initiation and progression. Later, the 
development of cell separation methods for murine and human hematopoietic precursor 
cells allowed for the isolation of specific target cells, in large quantities and with high cell 
population purity (Belvedere et al., 1999). Together with the utilization of retroviral 
expression vectors, which enable stable integration and expression of a transgene of choice, 
these cell isolation procedures represent a significant methodological improvement for 
leukemia modeling approaches in the hematopoietic tissue. With these technologies in hand, 
the genetic lesions of leukemia can be better modeled in the appropriate cell compartment. 
By performing cell biology experiments and tumor sample deep sequencing it became clear 
that both solid tumors and hematological malignancies depend on multiple oncogenic 
alterations to ultimately result in cellular transformation (Hanahan & Weinberg, 2000, 2011; 
Kinzler & Vogelstein, 1996). Additionally, the overall number of mutated genes in solid 
tumors was found to be higher than in leukemias. These observations resulted in the 
formulation of the multi-hit model of tumorigenesis. Initiating mutations induce stem cell 
expansion and survival, thereby allowing for the occurrence of additional genetic alterations 
that result in the progression of malignant transformation. The later stages of this process 
are characterized by uncontrolled proliferation with overgrowth of the ´healthy´ cell 
compartment and metastasis, in the case of solid tumors. This multi-hit cancer model has 
been well described for colon cancer by Kenneth W. Kinzler and Bert Vogelstein (Kinzler & 
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Vogelstein, 1996). Similarly, it has been suggested for hematopoietic malignancies, that only 
a concerted signaling network resulting from the activity of several activated oncogenes 
leads to full transformation of preleukemic cell clones. However, the exact chronological 
order of these genetic events and the causality of their mutual cooperation are hardly 
understood (Schuringa et al., 2010).  
Myeloid leukemia represents a well-depicted tumor entity in terms of molecular pathogenesis. 
It is characterized by an uncontrolled proliferation behavior based on the aberrant self-renewal 
capacity of the myeloid progenitor cell compartment including the erythroid, monocytic and 
granulocytic lineages. Depending on the morphology and genetics of the cells and its clinical 
progression, myeloid leukemia is classified as either acute myeloid leukemia (AML) or chronic 
myeloid leukemia (CML). AML is distinguished by the rapid proliferation of immature 
myeloid progenitor cells, which overgrow the normal hematopoietic cells. AML is the most 
common acute leukemia, which predominantly affects adults. Its incidence strongly increases 
with age, with a median age at diagnosis of 65 years, suggesting that several oncogenic events 
are required for the onset and progression of the disease (Estey & Dohner, 2006). If left 
untreated, the disease proceeds rapidly and is typically fatal within weeks or months. To date, 
numerous AML-specific fusion genes and mutations have been described (Look, 1997). 
Chromosomal translocations and mutations involving the AML1 gene are amongst the most 
common alterations found in AML (Schnittger et al., 2011). AML1 is an essential transcription 
factor that controls the myeloid cell differentiation of progenitor cells into mature blood cells. 
Both point mutations and chromosomal translocations, such as t(8;21) and t(3;21), disrupt the 
physiological function of AML1 and hinder the normal maturation process of the progenitor 
cells (Niebuhr et al., 2008). IIn addition, mutations of the receptor tyrosine kinase, c-kit, are 
frequently detected in these cells and seem to be associated with poor prognosis due to their 
correlation with higher relapse rates after chemotherapy (Boissel et al., 2006; Paschka et al., 
2006). Mutations of the nucleophosmin (NPM1) gene are also frequently observed in AML. 
This gene is involved in multiple cellular processes including protein shuttling between the 
nucleus and cytoplasm, RNA biogenesis, cell cycle control and transcriptional regulation. It is 
also described as a cellular stress sensor associated with the p53-dependent apoptosis pathway 
(Grisendi et al., 2006). Commonly identified NPM1 mutations render this protein mislocalized 
to the cytoplasm. The oncogenic mechanisms behind this phenomenon are currently under 
intense investigation (Falini et al., 2010; Falini et al., 2007). Among the mutated kinases in 
AML, mutations of the FLT3 cytokine receptor gene are common and are associated with poor 
prognosis (Gilliland & Griffin, 2002; Meshinchi et al., 2001). Hyperactive FLT3 induces a strong 
intracellular signal transduction response, mainly by activating STAT5, a latent transcription 
factor important for self-renewal and proliferation of hematopoietic progenitors. For this 
leukemia entity, FLT3-inhibitors blocking its kinase activity are currently being tested in 
clinical trials (Wiernik, 2010). Isocitrate dehydrogenases, IDH1 and IDH2, represent genes that 
were recently identified to be frequently mutated in AML with adverse prognosis in 
cytogenetically normal leukemias (Mardis et al., 2009; Paschka et al., 2010). Mutations in IDH 
genes have also been found in human brain tumors, including gliomas. Interestingly, the 
accumulation of an intracellular metabolite, 2-hydroxyglutarate, was discovered in these 
tumor cells (Dang et al., 2009). This so-called ‘oncometabolite’ alters the genome-wide histone 
and DNA methylation patterns, thereby exerting oncogenic activity (Xu et al., 2011). 
Chronic myeloid leukemia is characterized by the increased proliferation rate of mature 
granulocytes and their precursors. The course of disease can be divided into three phases: 
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the chronic phase, the accelerated phase and the acute phase with typical features of AML 
(Sawyers, 1999). The t(9;22) chromosomal translocation, also called the Philadelphia 
chromosome, which generates the fusion protein BCR/ABL, is frequently observed in 
CML patient samples. The BCR-portion of the fusion protein triggers multimerization of 
the ABL portion, thereby locking the ABL kinase into a hyperactive state. BCR/ABL 
multimers induce constitutive intracellular proliferation and survival signaling, thereby 
triggering the development of leukemia (Hoelbl et al., 2010; Melo & Barnes, 2007). Over 
the last years, a breakthrough in the treatment of CML was achieved with the 
development of the ABL-kinase inhibitor, imatinib (Sawyers et al., 2002). BCR/ABL 
positive CML patients are now treated with one of several targeted, first-line therapies, 
including imatinib, dasatinib, and nilotinib, which have dramatically increased patient 
survival rates to nearly 90% since the advent of these therapies. These kinase inhibitors 
specifically inhibit the oncogenic tyrosine kinase activity of BCR/ABL. For the first time, 
an inhibitor has been developed that targets a driving oncogene with high efficiency, 
which is currently used in many clinical trials (Garcia-Manero et al., 2003). Later, it was 
found that imatinib also targets c-kit, a receptor tyrosine kinase frequently mutated in 
gastrointestinal stromal tumors (GIST), thereby widening the application spectrum of 
imatinib to include solid tumors (Demetri, 2002). Currently, large efforts are being made 
in the development of specific inhibitors for other oncoproteins. The elucidation of the 
molecular mechanisms controlling the process of leukemic transformation represents a 
prerequisite for the development of targeted oncogene inhibitors designed to improve 
current therapeutic strategies for myeloid leukemias.  
For both acute and chronic myeloid leukemia, ‘leukemia stem cells’ are most likely the 
origin of disease and are probably responsible for recurrence after chemotherapy (Trumpp 
& Wiestler, 2008). These leukemia stem cells share common features with normal stem cells. 
They are described as dormant or slowly cycling cells with an increased self-renewal 
capacity and a resistance to chemotherapeutic drugs. It has been proposed that they reside 
in the bone marrow niches and can fully regenerate the leukemia after standard 
chemotherapy. Perturbed self-renewal programs of leukemia stem cells represent a major 
problem for leukemia therapy. Even in BCR/ABL positive CML, for which a specific 
oncogene inhibitor is available, CML stem cells are resistant to imatinib treatment 
(Holyoake et al., 1999). Therefore, lifelong treatment of CML patients with tyrosine kinase 
inhibitors is necessary (Corbin et al., 2011; Diamond & Melo, 2011). 
Most of the current understandings of leukemogenic fusion genes and mutations have 
resulted from overexpression experiments using either cell line models or primary murine 
and human hematopoietic stem cells, both in vitro and in vivo. In these studies, leukemic 
gene products were usually expressed with the help of retroviral expression vectors 
resulting in ectopic and stable expression. This represents a convenient experimental 
strategy to model leukemia in mammalian hematopoietic stem and progenitor cells. The 
following sections will recapitulate the different retroviral expression vector systems used 
for modeling leukemia development and will summarize exemplary results acquired from 
studies of both the murine and human progenitor cell systems.  
2. Retroviral vector systems and expression cassettes 
When modeling leukemia in the mammalian hematopoietic system, there are two major 
strategies used to express a leukemia-associated gene product. The creation of knock-in or 
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transgenic mice enables robust transgene expression in vivo. However, transgene expression 
is usually not restricted to a certain tissue and permanent oncogene expression often causes 
delirious side effects, e.g. embryonic lethality, thereby impeding accurate analysis. 
Alternatively, genes can be delivered by retroviral vectors directly into the hematopoietic 
system via bone marrow transplantation of hematopoietic progenitors, transduced with the 
gene of interest (GOI). Gene marking of few cells also more precisely resembles leukemia 
development from a single cell clone. In addition, this method provides the advantage of 
rapid testing of numerous gene expression constructs in contrast to the time-consuming 
gene-manipulation of mice. Therefore, gamma-retroviral and lentiviral expression vector 
systems represent attractive and efficient techniques for the stable expression of a gene of 
interest in hematopoietic progenitor cells. Retroviruses are enveloped RNA viruses. Viral 
RNA is linear, single-stranded and approximately 7-12 kb in size. The common 
characteristic of retroviruses is their strategy of replication: the viral RNA is reverse 
transcribed into linear double-stranded DNA followed by its integration into the genome of 
the cell (Coffin et al., 2007). The most commonly used delivery system is the gamma-
retroviral vector system. These vectors are derived from the Moloney murine leukemia virus 
(Mo-MLV) genome (Kohn et al., 1987). The murine stem cell virus (MSCV) expression vector 
is one of the most frequently employed vector systems, as it enables stable and high 
transgene expression in virtually all cell types (Hawley et al., 1994). This vector is available 
with several marker genes, such as the enhanced green fluorescent protein (eGFP) and 
derivatives thereof, which are co-expressed via the internal ribosomal entry site (IRES) 
elements. One of the disadvantages of gamma-retroviral vectors is their inability to target 
non-dividing cells. Successful cell transduction is completely dependent on the breakdown 
of the nuclear membrane during mitosis (Roe et al., 1993). In contrast, lentiviral vectors, 
which are mostly derived from the HIV-1 genome, are able to integrate into both dividing 
and non-dividing cells (Lewis et al., 1992; Lewis & Emerman, 1994). Compared with 
gamma-retroviral vectors, lentiviral vectors have the capacity to incorporate larger 
transgenes, up to 10 kilobases, although vector titers decrease when using larger inserts 
(Matrai et al., 2010). The integration of retroviral vectors into the cell genome results in the 
stable and permanent expression of the transgene, which is transferred to all daughter cells 
during cell division. Therefore, retrovirally transduced oncogene expressing cells resemble 
cancer cells in that they pass their oncogenic alterations down to all progeny. However, 
during integration into the genome there is a risk of insertional mutagenesis (Baum, 2007). 
This must be kept in mind while analyzing the potential oncogenic effects of a transgene 
delivered by retroviral vectors. In general, gamma-retro as well as lentiviral vectors 
integrate into transcriptional units. Gamma-retroviruses tend to integrate either upstream or 
downstream of the start of transcriptional units (Wu et al., 2003), while lentiviral vectors 
integrate randomly within a transcriptional unit (Naldini et al., 2006). During retroviral 
integration into the genome of a cell, there is a risk of proto-oncogene activation close to the 
integration site of the vector driven by either the enhancer element or the promoter 
sequences present in the U3 region of the viral long terminal repeats (LTRs). Deletion of the 
U3 region within the LTRs and the insertion of an internal enhancer/promoter result in the 
formation of self-inactivating (SIN) vectors with the reduced risk of cellular oncogene 
activation (Yu et al., 1986). Retroviral particle production and transduction procedures 
represent convenient routine methods, which can be carried out in any laboratory with the 
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appropriate laboratory biosafety level. For safety reasons, genes required for the assembly 
of the viral particles, gag, pol and env, are expressed from separate, so-called helper 
plasmids. In contrast to the expression vector, which codes for the gene of interest, the 
helper plasmids do not contain coding sequences for the packaging signal. Therefore, 
transcribed RNAs from the helper plasmids are not incorporated into the virus particle. 
With these replication defective retroviral particles, only a single round of transduction is 
possible. Thus, the risk of generating replication competent virus particles during 
production is greatly reduced. Retroviral transduction efficacy can be improved by 
concentrating the viral particles via ultracentrifugation (Kanbe & Zhang, 2004; Naldini et 
al., 1996). Gamma-retroviral particles can be preloaded onto RetroNectin-coated surfaces. 
RetroNectin, a recombinant peptide consisting of a mixture of fragments of the fibronectin 
molecule, co-localizes the viral particles and target cells into close proximity, thereby 
strongly increasing the efficiency of transduction (Hanenberg et al., 1996). A standard 
protocol for routine gamma-retroviral particle production and transduction of suspension 
cells is provided in Table 1. Expression of the gene of interest is usually coupled to the 
expression of a marker gene. This allows for immediate determination of the viral 
transduction efficacy as well as for the identification of transduced cells for the 
measurement of proliferation, differentiation and cell death. EGFP is the most commonly 
used marker protein, which exhibits a bright green fluorescence after laser excitation at 
488 nm. Enrichment of vector-transduced fluorescent-labeled cells can be performed by 
fluorescence activated cell sorting (FACS). The usage of drug-selectable marker genes, 
such as neomycin and puromycin, represents another method used to obtain pure 
populations of transduced cells. Cellular expression of more than one transgene by 
retroviral vectors can be accomplished by a variety of strategies (Figure 1).  
The inclusion of an internal promoter allows for the expression of a second transgene 
when one transgene is expressed from the vector 5´-LTR. However, this approach also 
carries the risk of promoter interference with the vector LTR during retroviral particle 
production, thereby reducing vector titers and expression levels of the GOI (de Felipe et 
al., 1999). Another commonly employed strategy is the expression of two separate genes 
from one single transcript using the IRES element derived from the picornavirus 
(Gallardo et al., 1997). The IRES element allows for the initiation of mRNA translation in a 
5’ cap-independent manner (Mountford & Smith, 1995). However, expression levels of the 
two genes usually differ significantly. Typically, the gene located downstream is 
expressed at a level ten times lower than that of the other gene (Mizuguchi et al., 2000). 
The gene of interest and the marker gene can be fused to increase their stability and to 
allow for expression from one promoter. However, fusing two transgenes can result in 
functional restriction of the proteins caused by the fusion. Therefore, a short, flexible 
linker should be used to connect the proteins (Robinson & Sauer, 1998). Repeats of small 
side chain amino acids, such as glycine, serine and alanine, are well suited for the creation 
of linker sequences. The expression of two separate transgenes in equimolar amounts can 
be accomplished using self-cleaving 2A peptides, originating from the foot-and-mouth 
disease virus (Ryan et al., 1991). The 2A peptide sequence disrupts the peptide bond 
formation via a ribosomal skip mechanism, which releases the polypeptide from the 
translational complex and allows the production of the downstream translation product 
(Donnelly et al., 2001).  
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Step 1:  
Retroviral 
vector 
production 
 For retroviral vector particle production subconfluent (80%) 
adherent cell lines (e.g. HEK293T, HeLA) are co-transfected with 
the retroviral expression construct and the appropriate helper 
plasmids 
 6 hours (or overnight) after transfection, exchange the appropriate 
medium for the target cells 
 24 hours later, harvest the viral supernatant: centrifuge the viral 
supernatant at 1.500 rpm to pellet cell debris and filtrate the 
supernatant (0.22 m filter) 
 Virus supernatant is ready for transduction or can be stored at –
80°C for several months 
Step 2:  
Preparation of 
RetroNectin-
coated plates 
 One day before transduction (at least 6 hours), add 500 µl 
RetroNectin (RN) solution (50 µg/ml) to each well of a 24-well 
plate (non-tissue culture treated) and incubate overnight at room 
temperature 
 The next day, discard the RN solution (reusable up to 8 times), add 
1 ml stop solution (1xPBS+2% BSA) and incubate for 30 minutes at 
room temperature  
 Discard the stop solution, rinse 1x with HBSS solution and 1x with 
1xPBS 
 Coated plates are ready for virus preload (RN coated plates can be 
stored in 4°C with PBS) 
Step 3:  
Preload of 
viral particles 
 Quickly defrost the virus supernatant and dilute as necessary 
 Discard the 1xPBS and add the viral supernatant with the 
appropriate multiplicities of infection (MOI) 
 Centrifuge at 3000 rpm at 4°C for 20-25 minutes 
 Discard the viral supernatant and repeat the preload at least 3 
times, each with the appropriate volume (minimum: 500 l) 
Step 4:  
Transduction 
of target cells 
 Remove the remaining viral supernatant before adding the cells 
 Count the cells and dilute the cells to a concentration of 7.5x105 
cells/ml in the appropriate culture medium  
 Add 500 µl (minimum) cell suspension to each well and incubate 
at 37°C and 5% CO2 for at least 8 hours (or overnight) 
 Optional: The addition of protamine sulfate (4 µg/ml) might 
increase the transduction efficiency 
 Prepare a second RN coated 24-well plate and repeat the preload 
and transduction procedure for a second, third or fourth 
transduction (max. 2 transductions per day) 
 8 hours after the final transduction, exchange the medium and 
transfer the transduced cells into a fresh tissue-coated 24-well plate 
without RN 
 Optional: Wash the plate 3x with 1x PBS to collect the remaining 
cells from the plate  
Table 1. Vector particle production and transduction standard protocol for suspension cells 
with gamma-retroviral vectors. 
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Fig. 1. Retroviral co-expression vector constructs, including eGFP as a marker gene. The 
depicted co-expression vectors are based on a standard 5’-LTR driven retroviral expression 
vector (top). 2A elements allow for co-expression of several GOI at equimolar levels. For 
intracellular stabilization, the GOI can be fused to eGFP. An internal promoter, e.g. the CMV 
promoter, drives GOI 2 expression independently of GOI 1. LTR, long terminal repeats; 
GOI, gene of interest; IRES, internal ribosomal entry site; 2A, 2A peptide sequence; eGFP, 
enhanced green fluorescent protein; CMV, cytomegalovirus. 
In the context of the MSCV-based retroviral vectors, it has been shown that coupling four 
transgenes via three different 2A peptide cleavage sequences can generate four separate 
proteins both in vitro and in vivo. One restriction with this system is that the small remaining 
2A-tag at the N-terminal end of the protein may potentially affect protein function 
(Szymczak et al., 2004). Therefore, proper cleavage and function of the individual proteins 
should be carefully verified. Table 2 summarizes the advantages and disadvantages of the 
different expression cassettes used for the co-expression of two genes of interest.  
The lentiviral gene ontology (LeGO) vectors represent a useful collection of state-of-the-art 
expression vectors for functional gene analysis. These vectors contain the retroviral 
enhancer/promoter of the spleen focus-forming virus, which has a broad and high 
expression pattern. LeGO expression vectors are available with a wide spectrum of different 
fluorescent markers, e.g. Cerulean, eGFP, tdTomato and mCherry, which are expressed in 
combination with the gene of interest via IRES elements. LeGO vectors that contain 
fluorescent marker genes linked via 2A peptides to different drug-selectable genes, e.g. 
blasticidin, hygromycin, neomycin, puromycin or zeocin, are also available. Furthermore, 
the expression cassettes of these LeGO vectors are flanked by loxP sites, which allows for 
displacement of the transgene after introduction of the CRE recombinase (Weber, 2007; 
Weber et al., 2008; Weber et al., 2010). 
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 IRES 2A 2nd promoter 
(internal) 
Co-transduction 
Advantage Expression of 2 
separate 
transgenes 
Equal 
expression 
levels of the 2 
genes 
Expression of 2 
separate 
transgenes 
Independent 
expression; 
results in single 
and double 
transduced cells 
Disadvantage 10x lower 
expression of the 
downstream gene
Remaining 2A 
tag at the end of 
the N-terminal 
protein 
Low titer of 
viral particles  
Low rate of double 
transduced cells; 
increases risk of 
insertional 
mutagenesis 
Literature  Gallardo et al., 1997
Mizuguchi et al., 
2000 
Szymczak et al., 
2004 
 
Felipe et al., 1999 Rizo et al., 2010 
Table 2. Overview of expression cassette elements for co-expression of two genes of interest. 
To accurately characterize oncogene activity it is important to have the ability to selectively 
induce and terminate oncogene expression. This is particularly important if the delivered 
gene product is toxic at high concentrations. The regulation of gene expression can be 
achieved by using the tetracycline-controlled transactivator (tTA)-responsive promoter (Tet-
system), a prokaryotic inducible promoter system that is also applicable to mammalian cells 
(Gossen & Bujard, 1992). The Tet system comprises two components: one component that 
drives expression of the transactivator (tTA) and a second component that contains the 
(tTA)-responsive promoter element for transgene expression. In the first developed tet-off 
system, the transactivator binds to the promoter in the absence of tetracycline. The addition 
of tetracycline inhibits its binding, thereby resulting in inhibition of transgene expression 
(Gossen et al., 1995). To avoid constant tetracycline supplementation, a reverse system (‘tet-
on’ system) allows for transgene expression only in the presence of doxycycline, a 
tetracycline derivate (Gossen et al., 1995). Traditionally, transactivator and promoter 
components had to be introduced by two separate transduction steps to obtain inducible 
gene expression. The development of an ‘all-in-one’ vector system circumvents this 
complication. In this system, all components required for tet-regulated transgene expression 
have been inserted as a bidirectional expression cassette (Heinz et al., 2011). Another means 
of intracellular oncogene dosage control is the regulation at the protein level. With this type 
of expression control, the gene of interest can be fused to a small destabilizing domain, 
thereby mediating the intracellular destruction of the protein by targeting it for proteasomal 
degradation. Degradation of the fusion protein can be specifically blocked by cell 
membrane-permeable small molecules, which bind to and inhibit the destabilizing domain 
mediated degradation, thereby resulting in the accumulation of the expressed transgene 
(Banaszynski et al., 2006). 
3. Murine progenitor cells 
Murine hematopoietic stem and progenitor cells have been well characterized. To study 
these cell types, progenitor cells can be simply isolated from the bone marrow. After femora 
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and tibia preparation, bone marrow cells can be harvested by flushing the bones. Further 
purification of hematopoietic progenitor cells is typically carried out by ‘lineage depletion’. 
Using this method, differentiated ‘lineage positive’ cells, such as monocytes and 
macrophages, T- and B- cells, erythrocytes and granulocytes, are separated from their 
committed precursors, the ‘lineage negative’ fraction. Freshly isolated, complete bone 
marrow suspension cells are incubated with a mixture of magnetically labeled antibodies 
against cell surface markers for mature blood cells, typically B220, CD4, CD8, Gr-1, Mac-1 
and Ter-119. Separation of the lineage negative progenitor cell fraction is performed by 
passing the labeled and non-labeled cells through magnetic columns (Challen et al., 2009).  
Amongst all vertebrates, the murine hematopoietic system is the best characterized. For the 
subdivision of stem and progenitor cell populations, the LSK- and SLAM-markers have 
become widely accepted. LSK (lin-, Sca1+, c-kit+) cells lack the markers of mature blood cells 
and simultaneously express high levels of the stem cell markers, Sca1 and c-kit. As little as 
one hundred LSK cells have been shown to be sufficient for the long-term multilineage 
repopulation of lethally irradiated recipient mice (Okada et al., 1992). The LSK cell 
compartment can be further separated into hematopoietic stem cells (HSCs) and multipotent 
progenitors (MPPs) depending on their diverse expression pattern of the family of ‘signaling 
lymphocyte activation molecule’ (SLAM) receptors (Kiel et al., 2005). The SLAM cell surface 
marker, CD150, is exclusively expressed on HSCs, whereas CD244 is expressed by 
transiently reconstituting MPPs. CD34 and Flt3 expression patterns further allow for the 
discrimination between long term-HSC (LT-HSCs; CD34-/Flt3-) and short term HSCs (ST-
HSCs; CD34+/Flt3+) (Adolfsson et al., 2001; Osawa et al., 1996). ST-HSCs have a reduced 
self-renewal capacity for a restricted time compared with the life-long self-renewal capacity 
of LT-HSCs (Adolfsson et al., 2001; Morrison & Weissman, 1994; Yang et al., 2005). Because 
the murine hematopoietic system has been well characterized, with precisely classified and 
characterized stem and progenitor cell compartments, and simple precursor cell purification 
procedures have been established and optimized, murine hematopoietic progenitor cells are 
well suited for the functional analysis of oncogenic fusion genes and mutations associated 
with leukemia development.  
The cell transforming activity of a given leukemia-associated oncogene can be measured by 
performing an in vitro colony forming unit (CFU) assay. This assay allows for the 
quantification of colony forming progenitors and their iterative replating capacity. 
Hematopoietic progenitor cells expressing the gene of interest are plated in methylcellulose 
at low density. In general, normal progenitor cells only form colonies in the first round of 
plating. However, oncogene-expressing cells are able to confer serial replating capacity for 
several rounds of plating. For example, cells expressing the t(8;21) translocation product, 
AML1/ETO, are able to confer serial replating for up to 13 rounds of plating (Rhoades et al., 
2000). Transgene expressing murine progenitor cells can also be cultivated in liquid 
suspension cultures. Here, cytokines such as IL3, IL6 and SCF must be supplemented 
continuously. Under these ex vivo cultivation parameters specific for cell differentiation, 
proliferation and apoptosis can be measured under various cell culture conditions, such as 
serum or cytokine deprivation and hypoxic conditions, which imitate the hypoxic niches of 
the bone marrow.  
Gene modified precursor cells can be further examined in vivo in a mouse transplantation 
model. In this case, immediately after retroviral gene transfer, lineage depleted bone 
marrow cells stably expressing the oncogene of interest are transplanted into lethally 
irradiated syngeneic recipient mice. The transplantation is performed by injection of gene-
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modified cells into the tail vein or the retro-orbital sinus of recipient mice (Larochelle et al., 
1995). For successful hematopoietic rescue, transplanted cells must reach the appropriate 
milieu in the bone marrow niches, which supports their proliferation and differentiation; 
this cell migration process is referred to as ‘homing’ (Szilvassy et al., 1999). To analyze 
disease progression in mice following the transplantation of progenitor cells body weight 
and blood profile values must be documented carefully over time. If transplanted mice 
develop any symptoms of leukemia, e.g. sudden body weight reduction, increasing 
peripheral leukocyte counts or poor general health conditions, they should be sacrificed and 
analyzed. Blood cells isolated from the periphery, spleen and bone marrow compartment 
can be studied separately. Flow cytometric analysis conveniently allows for the detection of 
oncogene expressing blood cells by discerning the expression of the fluorescence marker 
proteins. Gene marked cells can be examined for cellular differentiation (CD differentiation 
marker), the proliferation/cell cycle profile and apoptosis by AnnexinV-staining, for 
example. FACS based methods allow for the parallel analysis of transduced and non-
transduced cells, using the latter as the internal experimental control. Transgene expression 
of leukemic cells must be analyzed by RT-PCR and western immunoblotting, which assesses 
mRNA and protein levels, respectively. There are highly specific antibodies that can detect 
epitope-tagged oncoproteins, e.g. Ha- or Flag-tagged proteins, even at very low expression 
levels (Terpe, 2003). To exclude the potential oncogenic effects of vector-mediated 
insertional mutagenesis, clonality and integration site analysis must be performed carefully. 
The oncogene activity of the expressed transgene can be accurately validated by analyzing 
the downstream signal transduction pathways of the cell. For example, phosphorylated 
STAT5 and CRKL are regarded as downstream indicators of oncogenic BCR/ABL signaling. 
Bone marrow and spleen, which are the target organs of leukemic origin, and peripheral 
blood must be analyzed for the presence of immature blast cells. This can be carried out by 
conventional blood smear and flow cytometric analysis. For organ histology, samples of 
each organ, including the spleen, liver, lymph nodes and thymus, are transferred into 
paraffin, sectioned and examined. Hematoxylin and eosin are the most commonly used 
staining solutions in histology for light microscopical analysis. A final validation of the 
leukemia must be demonstrated by re-transplantating the leukemic blood cells into 
secondary lethally irradiated recipient mice. In these secondary transplanted mice, leukemia 
onset should appear much earlier than in primary recipients. In 2002, Kogan et al published 
the ‘Bethesda proposals for the classification of hematopoietic neoplasms in mice’ (Kogan et 
al., 2002). As with the World Health Organization (WHO) classification of human disorders, 
theses proposals utilize morphologic, immunophenotypic, clinical, biological and genetic 
characteristics to classify neoplasms.  
Both methods, the colony-forming assay and the mouse transplantation model are 
commonly used techniques for the investigation of the transforming potential of oncogenes 
in leukemia (Figure 2).  
The following examples illustrate both the genetic and biochemical approaches utilizing 
murine hematopoietic progenitor cells for leukemia modeling.  
The acute promyelocytic leukemia (APL) associated t(15;17) translocation product, 
PML/RAR, is one of the most studied fusion proteins associated with AML (Puccetti & 
Ruthardt, 2004). In the clinical setting, APL patients not only respond well to ‘all trans 
retinoic acid’ (ATRA) therapy, which has been well documented (Huang et al., 1988), but 
also benefit from treatment with arsenic trioxide (Chen et al., 1997), which exerts a profound 
anti-cancer effect by inducing the degradation of the PML/RAR oncoprotein. Retroviral 
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expression of PML/RAR in murine progenitor cells efficiently induces leukemia 
development in transplanted lethally irradiated recipient mice (Minucci et al., 2002). The 
efficacy of arsenic trioxide and ATRA has been recapitulated in PML/RAR mouse models 
displaying the impressive anti-leukemia effects of both substances (Rego et al., 2000). 
Furthermore, in transplantation models based on ATRA-resistant APL cell lines, treatment 
with arsenic trioxide significantly decreases tumor formation (Kinjo et al., 2000). Zhang et al 
have further showed that arsenic trioxide functions by directly binding to PML/RAR. The 
researchers identified cysteine residues within the PML portion that are directly bound by 
arsenic trioxide, which triggered SUMOylation and subsequent degradation of the 
oncoprotein (Zhang et al., 2010).  
 
 
Fig. 2. Functional analysis of gene-modified murine/human hematopoietic progenitor cells. 
Experimental procedures include cloning of the retroviral expression vector, viral particle 
production, hematopoietic progenitor cell isolation, transduction and functional analysis in 
methylcellulose assays, liquid cultures and murine syngeneic or xenogeneic mouse 
transplantation models. GOI, gene of interest; MSCV, murine stem cell virus; LTR, long 
terminal repeats; lin-, lineage negative. 
Other reports have described that oncogene expression experiments involving murine 
progenitor cells supported the clinical finding reporting a highly leukemogenic splice 
variant of the familiar AML1/ETO fusion gene resulting from the translocation t(8;21). 
Several groups have shown that the full length AML1/ETO protein does not lead to the 
development of leukemia when transplanting LSK bone marrow cells expressing 
AML1/ETO into syngeneic mice (de Guzman et al., 2002). However, in similar 
transplantation experiments performed by Yan and colleagues, one mouse developed 
leukemia 14 weeks after bone marrow transplantation. Further analysis showed that a C-
terminal truncated AML1/ETO protein was expressed in this mouse due to a one-base pair 
insertion into the full length AML1/ETO gene. Subsequently, the cloning and creation of 
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mice expressing the truncated protein by transplantation of transduced progenitor cells 
again revealed a rapid leukemia development (Yan et al., 2004). Consequently, these results 
led to the investigation and identification of a naturally occurring splice variant of 
AML1/ETO in t(8;21) patients by sophisticated gene expression analysis of patient material. 
This splice variant, termed AML1/ETO9A, is almost structurally identical to the truncated 
form expressed in the leukemic mouse. Expression of this newly discovered splice isoform 
in mice also induced rapid leukemia development (Yan et al., 2006). In conclusion, these 
oncogene expression experiments using murine progenitor cells led to the clinical 
identification of a potent oncogenic AML1/ETO splice variant. Further experiments must be 
performed to understand whether the AML1/ETO splice isoform is the driving oncogene in 
human t(8;21) leukemia cells. 
The usage of oncogene expressing vectors has also facilitated the understanding of the 
protein domain structure-function relationship. Biophysical and biochemical experiments 
have been used to identify highly conserved domains within several oncoproteins, which 
might represent valuable target structures for molecular intervention. This has been 
demonstrated with the AML1/ETO fusion protein. Here, a central region, the nervy 
homology region 2 (NHR2), was found to play an essential role in the leukemogenic activity 
of the fusion protein. Analysis of the crystal structure revealed a tetrameric formation that is 
essential for the serial colony formation capacity of murine progenitor cells in 
methylcellulose assays (Liu et al., 2006). By performing additional bioinformatic molecular 
modeling analyses, five amino acids were identified within the large NHR2 tetramer-
interface that are important for oligomer formation. Substitution of these critical residues led 
to the conversion of tetramers into dimers with the complete loss of the transforming 
abilities of AML1/ETO. Transplantation of retroviral infected murine bone marrow cells 
expressing the AML1/ETO protein harboring these five substitutions showed that these 
amino acids play a critical role in transformation, as the mice failed to develop leukemia. 
Interestingly, the identified amino acids are clustered in one region at the top of the NHR2 
dimer surface, thereby representing a potential target site for molecular intervention 
(Wichmann et al., 2010). These findings, which reveal the molecular determinants of 
oncogene activity, are the result of a productive combination of bioinformatics, biochemical 
and cell-biological analyses. Furthermore, proof of concept of oncogene targeting was 
demonstrated using a synthetic oligomerization domain. This domain was integrated into 
the AML1/ETO fusion gene, thereby replacing the NHR2 tetramer domain. Specific 
inhibitors that disrupt the oligomerization of this synthetic domain within AML1/ETO 
completely blocked the replating capacity of retrovirally transduced AML1/ETO expressing 
murine progenitor cells (Kwok et al., 2009).  
By expressing leukemia fusion genes in murine cells, one can assess exactly which gene 
product from a balanced translocation, which often generates two different reciprocal fusion 
genes, is responsible for driving the leukemic activity. Bursen and colleagues have reported 
interesting findings regarding the function of the reciprocal fusion proteins, AF4/MLL and 
MLL/AF4, which are generated by the chromosomal translocation t(4;11) in high-risk infant 
acute mixed lineage leukemia. They analyzed the leukemia-inducing capacity of these two 
fusion genes in mice by transplantation of retrovirally transduced Lin-/Sca1+ cells 
expressing either one or both of the reciprocal fusion genes. They could show that 
expression of AF4/MLL alone was sufficient to promote leukemia development, while the 
reciprocal translocation, MLL/AF4, completely lacked leukemogenic potential (Bursen et al., 
2010).  
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4. The human CD34+ progenitor cell system 
Human blood progenitor cells are characterized by the high expression levels of the cell 
surface marker CD34 and the absence of CD38 expression (CD34+/CD38-). CD34 is a 
member of the single-pass transmembrane sialomucin protein family, which is expressed in 
early hematopoietic and vascular-associated tissues; however, little is known about its exact 
biological function (Furness & McNagny, 2006). There are a variety of ways to obtain 
hematopoietic CD34+ cells from the human body. The cells can be isolated from the 
peripheral blood by leukapheresis after stimulation and mobilization of the bone marrow 
precursors with G-CSF (granulocytic colony stimulating factor). Bone marrow aspiration 
represents the classical but invasive isolation method, which also allows for the isolation of 
large numbers of CD34+ cells. A third option involves the usage of placental derived cord 
blood cells of which the quality/stemness and engraftment potential are superior to that of 
adult CD34+ stem cells (Hao et al., 1995). The efficient enrichment of human hematopoietic 
CD34+ cells can be achieved by immunomagnetic cell sorting, which represents a standard 
and convenient method in laboratory work (Clarke & Davies, 2001). Magnetic labeled CD34-
antibodies are used to recover high-purity populations of CD34+ cells by passing cells 
through magnetic columns. Isolated CD34+ cells can then be used for clinical and 
experimental purposes. For transgene expression studies, the cells can be manipulated by 
retroviral transduction immediately after recovery or after a short pre-cultivation in a 
cytokine cocktail, which usually contains IL-3, IL6 and SCF for cell cycle activation. Like the 
murine system, transduced human CD34+ cells can be propagated in vitro in 
methylcellulose assays for colony formation as well as in long-term liquid cultures used to 
assess self-renewal and proliferation/expansion capacities (Figure 1). Furthermore, human 
CD34+ cells expressing leukemic gene products can be transplanted into severe combined 
immunodeficient (NOD/SCID) mice (xenotransplants). Additionally, the NOG (NOD/Shi-
scid/IL-2Rγnull) mice accept heterologous transplanted cells more easily than any other type 
of immunodeficient nude or NOD/SCID mice. Therefore, the NOG mouse system is a 
highly efficient recipient model for the engraftment, proliferation and differentiation of 
human cells (Ito et al., 2002). 
The transformation of human cells requires additional genetic alterations when compared 
with their murine counterparts (Hahn et al., 1999; Rangarajan & Weinberg, 2003). This is 
reflected by the observation that singular expression of several oncogenes induces leukemia 
in the murine system but fails to transform human CD34+ cells in the NOD/SCID 
humanized leukemia mouse model. Further evidence of this concept has been demonstrated 
by gene expression analysis of healthy individuals. Here, oncogenes such as BCR/ABL and 
AML1/ETO have been frequently detected in individuals completely lacking any sign of 
disease (Song et al., 2011). As CD34+ cells represent the human hematopoietic 
stem/progenitor cell population, these cells can be regarded as appropriate target cells used 
to study the biological effects of oncogenes in human leukemia development. 
The following passages provide an overview of recent experiments addressing the 
leukemogenic activity of several myeloid leukemia associated oncogenes expressed alone or 
in combination in human hematopoietic CD34+ progenitor cells. In all cases, genes were 
delivered using gamma-retroviral vectors co-expressing the marker genes eGFP or dNGFR 
(truncated nerve growth factor receptor), which allowed for the convenient detection of 
gene-modified cells by FACS analysis. 
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Grignani et al have reported that ectopic expression of PML/RAR in human CD34+ ex vivo 
cultures rapidly induced the cellular differentiation of progenitor cells towards the 
promyelocytic stage, followed by a block in further terminal differentiation into 
granulocytes, which resembled typical features of primary human acute promyelocytic 
leukemia (Grignani et al., 2000). In cytokine deprived liquid cultures, PML/RAR 
expressing cells survived and continued to expand, whereas control cells stopped 
proliferation and died by apoptosis. The terminal differentiation block induced by 
PML/RAR could be overcome by treatment with ATRA, a drug that has dramatically 
improved the overall survival of APL patients. They further demonstrated that a mutation 
of the N-CoR repressor binding interface within the PML portion of the fusion protein 
completely disrupted the observed biological effects, thereby suggesting that N-CoR 
triggered transcriptional repression is an essential prerequisite for PML/RAR oncogene 
activity in human hematopoietic progenitor cells.  
Among the AML oncogenes, hyperactive tyrosine kinases play a major role in disease 
development and have gathered much attention since the kinase inhibitor imatinib has been 
proven to be highly beneficial for BCR/ABL positive CML patients (Druker et al., 1996; 
Sawyers et al., 2002; Brandts et al., 2007). Chung and colleagues retrovirally expressed a 
related constitutive active tyrosine kinase, FLT3-ITD, which is frequently found in AML 
patient samples associated with poor prognosis (Gilliland & Griffin, 2002). Stable expression 
of FLT3-ITD conferred a strong short-term proliferative signal in human CD34+ cells with 
enhanced erythropoiesis for two weeks after transduction ex vivo. The cells were blocked in 
terminal differentiation and colony formation was enhanced when compared with control 
cells. These effects could be partially substituted by expression of a constitutive active 
STAT5 mutant, a major downstream target of the hyperactive FLT3-ITD kinase. Moreover, 
FLT3-ITD triggered effects that could be blocked via inhibition with the FLT3-inhibitor 
tyrphostin (Chung et al., 2005). Despite these significant effects, FLT3-ITD transgene-
expressing CD34+ cells are neither able to expand further in ex vivo cultures nor able to 
induce leukemia in the NOD/SCID mouse transplantation model.  
Stable ectopic expression of several leukemogenic fusion genes resulting from chromosomal 
translocations leads to enhanced ex vivo CD34+ cell expansion for up to several months 
(Abdul-Nabi et al., 2010). This has previously been shown for the t(8;21) associated fusion 
protein AML1/ETO, which is capable of expanding human CD34+ cells ex vivo for several 
months with a cumulative cell expansion of more than 1015-fold. Retroviral expression of 
AML1/ETO resulted in a sustained proliferation potential using a cytokine cocktail that 
included IL3, IL6, SCF, FLT3, GM-CSF, TPO and EPO, all at low concentrations. The cells 
display the typical differentiation block as observed in myeloid blast cells and grow out 
from a mixed culture of transduced and non-transduced cells. Even after several weeks in ex 
vivo culture, the cells are capable of colony formation in methylcellulose assays and, more 
importantly, of engraftment into immunodeficient NOD/SCID mice (Mulloy et al., 2003; 
Mulloy et al., 2002). Phenotypically, a subpopulation of the cells continues to express CD34, 
while the majority of the cells express the myeloid specific markers CD13 and CD33, in the 
absence of erythroid markers. Continuous expansion of the cells completely depends on the 
CD34+ subgroup. Erythroid differentiation was shown to be blocked by the AML1/ETO 
fusion protein via direct inhibition of GATA1 transcription factor activity (Choi et al., 2006). 
However, expression of AML1/ETO does not lead to leukemia development in transplanted 
immunodeficient NOD/SCID mice, suggesting that additional genetic hits must occur for 
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full-blown AML development. Similar results were obtained from analysis of the inv(16) 
fusion protein CBFB/MYH11. Expression of this fusion gene also caused enhanced 
proliferation and expansion of CD34+ cells over several months with retention of the 
engraftment potential in NOD/SCID mice. However, as also observed with AML1/ETO, 
transplanted mice do not develop leukemia (Wunderlich et al., 2006). Therefore, both 
oncogenes confer a preleukemic status and subsequent alterations are required for the 
transition to overt leukemia. 
To decipher the genetic signature of AML, Abdul-Nabi and colleagues have assessed 
various AML-associated fusion proteins for their ability to enhance CD34+ cell expansion ex 
vivo and subsequently analyzed their gene expression profiles (Abdul-Nabi et al., 2010). In 
this study, experiments were also performed with gamma-retroviral vectors expressing the 
fusion genes AML1/ETO, PML/RAR, MLL/AF9 and NUP98/HOXA9 together with 
eGFP. To identify key target genes responsible for the expansion of CD34+ cells the authors 
performed gene array analysis of FACS-sorted eGFP+ cells expressing the indicated 
oncogenes, which identifies the induced and repressed target genes during the ex vivo 
selection process. One interesting candidate gene that was shown to be specifically 
upregulated due to both AML1/ETO and PML/RAR expression was the p53-inhibiting 
molecule MDM2. The authors could further show that activation of the gatekeeper protein 
p53, by blocking the MDM2-p53 protein-protein interaction with the small molecule 
compound Nutlin-3, was sufficient to completely block AML1/ETO induced selection and 
expansion of CD34+ progenitor cells. Therefore, Nutlin-3 is proposed to function as an 
inhibitor for AML1/ETO positive leukemias by reactivating p53 and consecutively 
eliminating the leukemic cells via the induction of apoptosis. Two independent groups have 
shown that retroviral expression of the NUP98/HOXA9 fusion gene, which is found in 
myelodysplastic syndrome (MDS) and AML patients, resulted in a similar outgrowth of 
transgene expressing cells with maintenance of self-renewal potential ex vivo and increased 
engraftment capacity in NOD/SCID mice (Chung et al., 2006; Takeda et al., 2006). This 
outgrowth was accompanied by high levels of HOX gene expression, a typical feature for 
this leukemia entity.  
Regardless of their remarkable ex vivo cell expansion properties, the AML associated gene 
products described above, PML/RAR, FLT3-ITD, NUP98/HOXA9 and AML1/ETO, were 
not able to independently induce leukemia in transplanted NOD/SCID mice. Therefore, it is 
likely that additional genetic alterations are required for full cellular transformation in AML. 
In this regard it was shown that oncogenic RAS signaling, triggered by N-RasG12D 
overexpression, does increase AML1/ETO engraftment capacity in NOD/SCID mice but is 
still not sufficient to overcome the leukemia onset defect in the NOD/SCID mouse model 
(Chou et al., 2011).  
Interestingly, MLL rearrangements are typically found in aggressive infant or therapy 
related leukemias (Aplan, 2006). In contrast to AML derived gene products, ectopic 
expression of either MLL/AF9 or MLL/ENL mixed-lineage leukemia fusion genes, as a 
single genetic event, results in the development of myeloid or lymphoid leukemias in the 
NOD/SCID mouse model approximately 100 days after transplantation (Barabe et al., 2007; 
Wei et al., 2008). Morphological analysis has revealed that AML and B-ALL leukemias are 
associated with both MLL rearrangements. Remarkably, ex vivo expanded cells gave rise to 
leukemia in NOD/SCID mice, even after 70 days of in vitro culture prior to transplantation 
in sublethally irradiated mice. The reasons for the striking differences between AML and 
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MLL fusion genes in their ability to induce leukemia onset in NOD/SCID mice are 
completely unknown. A direct comparison of deregulated genes may reveal which 
additional pathways are activated in MLL leukemic human CD34+ cells. 
Recently, a report was published describing a true oncogenic cooperativeness in human 
CD34+ cell expansion and leukemia induction in NOD/SCID mice (Rizo et al., 2010). The 
authors convincingly have shown that retroviral co-expression of the CML associated 
oncogene, BCR/ABL, and the polycomb ring finger oncogene, BMI1, leads to leukemia 
induction within 4-5 months after transplantation. The isolated human leukemia cells were 
re-transplantable into secondary recipient mice, which induced leukemia with a shortened 
latency. In vitro, the co-expression of both oncogenes in human CD34+ cells allowed for the 
establishment of myeloid and lymphoid long-term cultures with self-renewing properties. 
This report also describes a series of valuable cell culture methods for in vitro analysis of 
CD34+ cell proliferation and self-renewal. Finally, the authors have demonstrated that 
retroviral introduction of BMI1 into primary leukemia cells from CML chronic-phase 
patients elevated the proliferative capacity and self-renewal properties of the leukemia cells, 
while shRNA knockdown of BMI1 in blast crisis CML cells completely blocked their 
proliferation potential. These results highlight BMI1 as an attractive molecular target for 
blast crisis CML cells, which is especially important given the rates of BCR/ABL positive 
leukemic stem cell resistance to kinase inhibitors such as imatinib (Corbin et al., 2011). 
However, the exact molecular mechanisms of BCR/ABL and BMI1 oncogenic co-operation 
have to be addressed in further studies. 
In conclusion, human CD34+ blood progenitor cells represent a powerful cell biology tool 
used for the analysis of leukemogenic gene product activity. Methods of isolation and 
purification of CD34+ cells have significantly improved and are broadly available for 
researchers. The cells can be propagated ex vivo and oncogene activity can be analyzed for a 
wide range of biological parameters, including differentiation, proliferation, self-renewal, 
senescence and apoptosis, using standard cell biology methods. CD34+ suspension cells can 
be cultured ex vivo as liquid cultures or on stromal layer cells. With the possibility to 
transplant these cells into sublethally irradiated NOD/SCID mice this is an ideal model 
system to study the function of human leukemia-associated oncogenes. 
5. Conclusions 
Powerful retroviral expression vectors and standardized enrichment technologies, which are 
used for the isolation of hematopoietic precursor cells from the murine and human bone 
marrow compartment, efficiently enabled the accurate modeling of leukemia initiation and 
progression in the appropriate cell compartment. Currently available expression vectors 
allow for the simultaneous expression of several genes, including oncogenes, marker genes 
for detection and selection genes used to isolate modified cells, which represent practical 
tools for modeling leukemia progression in hematopoietic cells. Among the introduced 
strategies, the humanized mouse model based on human CD34+ precursor cell 
transplantation into NOD/SCID mice represents a credible model system to study human 
leukemia. As described here, the expression of single oncogenes such as BCR/ABL and 
AML1/ETO, which are primarily found in older patients, does not lead to leukemia 
development, implying that disease develops as a result of secondary mutations. In contrast, 
the expression of several MLL fusion proteins, which are typically found in younger 
patients, was found to be sufficient to trigger leukemia development with high penetrance. 
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In total, these approaches will lead to a better understanding of the genetic alterations that 
are required for the onset of cellular transformation. Furthermore, these studies have the 
potential to propel the development of effective drugs designed to eradicate leukemia cells. 
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